Compare ELTX & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | DIT |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Food Distributors |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 64.4M |
| IPO Year | 2014 | 1996 |
| Metric | ELTX | DIT |
|---|---|---|
| Price | $1.92 | $67.56 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.67 | N/A |
| AVG Volume (30 Days) | ★ 324.7K | 264.0 |
| Earning Date | 11-12-2026 | 08-05-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ 1.40 |
| Revenue | $2,301,000.00 | ★ $1,392,388,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $48.26 |
| Revenue Growth | N/A | ★ 5.30 |
| 52 Week Low | $1.71 | $59.15 |
| 52 Week High | $16.00 | $122.00 |
| Indicator | ELTX | DIT |
|---|---|---|
| Relative Strength Index (RSI) | 23.58 | 47.94 |
| Support Level | $1.71 | $59.15 |
| Resistance Level | $3.32 | $74.55 |
| Average True Range (ATR) | 0.11 | 0.53 |
| MACD | 0.04 | 0.39 |
| Stochastic Oscillator | 29.88 | 35.74 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.